scholarly article | Q13442814 |
review article | Q7318358 |
P50 | author | Jos Kleijnen | Q28037365 |
Nasuh Buyukkaramikli | Q61092778 | ||
Janine Ross | Q63373125 | ||
Nigel Armstrong | Q92354906 | ||
Gill Worthy | Q101239876 | ||
P2093 | author name string | Maiwenn J Al | |
Fiona J Clay | |||
Hedwig M Blommestein | |||
Rob Riemsma | |||
Johan Severens | |||
P2860 | cites work | The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology | Q29615701 |
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 | ||
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Q29620917 | ||
Disparities in gastric cancer chemotherapy between the East and West | Q36472210 | ||
Health state utilities for metastatic breast cancer | Q36591214 | ||
Health state utilities for non small cell lung cancer | Q36963976 | ||
Elicitation of health state utilities in metastatic renal cell carcinoma | Q37708305 | ||
Geographic differences in approach to advanced gastric cancer: Is there a standard approach? | Q38114265 | ||
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). | Q42608504 | ||
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma | Q44177579 | ||
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 400 | Q44754243 | ||
A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy | Q44923328 | ||
Race and ethnicity correlate with survival in patients with gastric adenocarcinoma | Q47633003 | ||
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial | Q48117450 | ||
Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. | Q53384216 | ||
Costs of palliative care in the community, in hospitals and in hospices in the UK | Q56562451 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
P433 | issue | 12 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | adenocarcinoma | Q356033 |
monoclonal antibody | Q422248 | ||
stomach neoplasm | Q4335552 | ||
esophageal neoplasm | Q56014520 | ||
antineoplastic combined chemotherapy protocols | Q66764603 | ||
P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
P304 | page(s) | 1211-1221 | |
P577 | publication date | 2017-12-01 | |
P1433 | published in | PharmacoEconomics | Q7180778 |
P1476 | title | Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal | |
P478 | volume | 35 |
Q99585277 | Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials |
Q94606068 | Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China |
Q94452251 | Molecular mechanisms of synergistic action of Ramucirumab and Paclitaxel in Gastric Cancers cell lines |
Q90470975 | Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal |
Q33806813 | Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category? |
Q57106177 | Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal |
Q64944976 | Value of information analysis in telehealth for chronic heart failure management. |
Q55210410 | Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals. |
Search more.